Targeting MDSCs using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma
Richard P. Tobin(Society of Surgical Oncology), Martin McCarter, Karl D. Lewis(University of Colorado Denver), Jessica S.W. Borgers(The Netherlands Cancer Institute), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Theresa Medina(University of Colorado Cancer Center), William A. Robinson(University of Colorado Anschutz Medical Campus), Kasey L. Couts(University of Colorado Anschutz Medical Campus), Dasha T. Cogswell(University of Colorado Anschutz Medical Campus), Dexiang Gao(University of Colorado Cancer Center), Eduardo Dávila(New Mexico State University), Robert J. Van Gulick(University of Colorado Anschutz Medical Campus), Dana M. Davis(Dalhousie University), Ross W. McFarland(Cancer Clinic), Victoria M. Vorwald(University of Colorado Anschutz Medical Campus), René González(University of Miami)
Cited by 1
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594